These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28730878)

  • 1. Investigational drugs in development for Hepatitis D.
    Rizzetto M
    Expert Opin Investig Drugs; 2017 Sep; 26(9):999-1005. PubMed ID: 28730878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hepatitis D: an unmet medical need.
    Caviglia GP; Rizzetto M
    Clin Microbiol Infect; 2020 Jul; 26(7):824-827. PubMed ID: 32120043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Hepatitis D.
    Rizzetto M
    Semin Liver Dis; 2018 Feb; 38(1):66-72. PubMed ID: 29471567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Hepatitis D; at a Standstill?
    Rizzetto M
    Dig Dis; 2016; 34(4):303-7. PubMed ID: 27170382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging concepts for the treatment of hepatitis delta.
    Elazar M; Glenn JS
    Curr Opin Virol; 2017 Jun; 24():55-59. PubMed ID: 28475945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.
    Lempp FA; Ni Y; Urban S
    Nat Rev Gastroenterol Hepatol; 2016 Oct; 13(10):580-9. PubMed ID: 27534692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBV/HDV Coinfection: A Challenge for Therapeutics.
    Koh C; Da BL; Glenn JS
    Clin Liver Dis; 2019 Aug; 23(3):557-572. PubMed ID: 31266627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
    Koh C; Canini L; Dahari H; Zhao X; Uprichard SL; Haynes-Williams V; Winters MA; Subramanya G; Cooper SL; Pinto P; Wolff EF; Bishop R; Ai Thanda Han M; Cotler SJ; Kleiner DE; Keskin O; Idilman R; Yurdaydin C; Glenn JS; Heller T
    Lancet Infect Dis; 2015 Oct; 15(10):1167-1174. PubMed ID: 26189433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
    Deterding K; Wedemeyer H
    AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis delta and HIV infection.
    Soriano V; Sherman KE; Barreiro P
    AIDS; 2017 Apr; 31(7):875-884. PubMed ID: 28121714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis delta: A state-of-the-art review and new therapies.
    Gilman C; Heller T; Koh C
    World J Gastroenterol; 2019 Aug; 25(32):4580-4597. PubMed ID: 31528088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
    Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A
    Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of delta hepatitis.
    Gunsar F
    Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hepatitis delta: Need for novel therapeutic options.
    Abbas Z; Abbas M
    World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection.
    Guo Z; King T
    Int J Mol Sci; 2015 Aug; 16(8):19537-52. PubMed ID: 26295228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
    Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çalişkan A; Karatayli E; Karatayli S; Bozdayi AM; Koh C; Heller T; Idilman R; Glenn JS
    Hepatology; 2018 Apr; 67(4):1224-1236. PubMed ID: 29152762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic hepatitis D at a standstill: where do we go from here?
    Ciancio A; Rizzetto M
    Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):68-71. PubMed ID: 24019153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future treatments for hepatitis delta virus infection.
    Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
    Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
    Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
    J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment options for delta virus: Is a cure in sight?
    Yurdaydin C
    J Viral Hepat; 2019 Jun; 26(6):618-626. PubMed ID: 30771261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.